Uvisa Health Aps

Ledelsesberetning

Udvikling i aktiviteter og økonomiske forhold 2023 saw the departure of one of the original co-founders of the company, leaving Ella Harris as the sole director and shareholder. The company secured additional funding 0f 1.432M dkk through the Innovation Fund Denmark InnoBooster grant, in addition to a convertible loan of 1M dkk from a single private angel investor, leading to the hire of two new key employees within Engineering and Medical Sciences. The company also entered the DTU Pilots programme funded by Industriens Fond, which helped fund further prototyping, leading to production of several technical and functional prototypes using components intended in the final product. Pre-clinical efficacy studies conducted throughout this year concluded that the light treatment under development is effective against the microbes of interest at very specific wavelengths and doses, and initial indication was given that the treatment can be further optimised to reduce the impact on non-pathogenic microbes. A research collaboration between the company, DTU, KU, Nordsjællands Hospital and Rigshospitalet was initiated to further investigate safety of the proposed treatment on excised human vaginal tissue. Results of this are expected in early 2024 but initial assessment is promising.